LCTX Quote, Financials, Valuation and Earnings

Exelixis has a net margin of -275.57% compared to Lineage Cell Therapeutics's net margin of 28.74%. Lineage Cell Therapeutics's return on equity of -22.68% beat Exelixis's return on equity of 29.53%.

Lineage Cell Therapeutics has a consensus price target of $3.92, signalling upside risk potential of 318.81%. On the other hand Exelixis has an analysts' consensus of $44.16 which suggests that it could grow by 1.12%. Given that Lineage Cell Therapeutics has higher upside potential than Exelixis, analysts believe Lineage Cell Therapeutics is more attractive than Exelixis.

Lineage Cell Therapeutics has a beta of 1.517, which suggesting that the stock is 51.713% more volatile than S&P 500. In comparison Exelixis has a beta of 0.280, suggesting its less volatile than the S&P 500 by 71.957%.

Lineage Cell Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exelixis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lineage Cell Therapeutics pays -- of its earnings as a dividend. Exelixis pays out -- of its earnings as a dividend.

Lineage Cell Therapeutics quarterly revenues are $1.5M, which are smaller than Exelixis quarterly revenues of $555.4M. Lineage Cell Therapeutics's net income of -$4.1M is lower than Exelixis's net income of $159.6M. Notably, Lineage Cell Therapeutics's price-to-earnings ratio is -- while Exelixis's PE ratio is 19.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lineage Cell Therapeutics is 20.64x versus 5.54x for Exelixis. Usually stocks with elevated PS ratios are considered overvalued.

Inovio Pharmaceuticals has a net margin of -275.57% compared to Lineage Cell Therapeutics's net margin of -30140.49%. Lineage Cell Therapeutics's return on equity of -22.68% beat Inovio Pharmaceuticals's return on equity of -125.47%.

Lineage Cell Therapeutics has a consensus price target of $3.92, signalling upside risk potential of 318.81%. On the other hand Inovio Pharmaceuticals has an analysts' consensus of $8.00 which suggests that it could grow by 279.15%. Given that Lineage Cell Therapeutics has higher upside potential than Inovio Pharmaceuticals, analysts believe Lineage Cell Therapeutics is more attractive than Inovio Pharmaceuticals.

Lineage Cell Therapeutics has a beta of 1.517, which suggesting that the stock is 51.713% more volatile than S&P 500. In comparison Inovio Pharmaceuticals has a beta of 1.344, suggesting its more volatile than the S&P 500 by 34.39%.

Lineage Cell Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lineage Cell Therapeutics pays -- of its earnings as a dividend. Inovio Pharmaceuticals pays out -- of its earnings as a dividend.

Lineage Cell Therapeutics quarterly revenues are $1.5M, which are larger than Inovio Pharmaceuticals quarterly revenues of $65.3K. Lineage Cell Therapeutics's net income of -$4.1M is higher than Inovio Pharmaceuticals's net income of -$19.7M. Notably, Lineage Cell Therapeutics's price-to-earnings ratio is -- while Inovio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lineage Cell Therapeutics is 20.64x versus -- for Inovio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Lexicon Pharmaceuticals has a net margin of -275.57% compared to Lineage Cell Therapeutics's net margin of -2004.36%. Lineage Cell Therapeutics's return on equity of -22.68% beat Lexicon Pharmaceuticals's return on equity of -90.8%.

Lineage Cell Therapeutics has a consensus price target of $3.92, signalling upside risk potential of 318.81%. On the other hand Lexicon Pharmaceuticals has an analysts' consensus of $2.58 which suggests that it could grow by 211.48%. Given that Lineage Cell Therapeutics has higher upside potential than Lexicon Pharmaceuticals, analysts believe Lineage Cell Therapeutics is more attractive than Lexicon Pharmaceuticals.

Lineage Cell Therapeutics has a beta of 1.517, which suggesting that the stock is 51.713% more volatile than S&P 500. In comparison Lexicon Pharmaceuticals has a beta of 1.003, suggesting its more volatile than the S&P 500 by 0.318%.

Lineage Cell Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexicon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lineage Cell Therapeutics pays -- of its earnings as a dividend. Lexicon Pharmaceuticals pays out -- of its earnings as a dividend.

Lineage Cell Therapeutics quarterly revenues are $1.5M, which are larger than Lexicon Pharmaceuticals quarterly revenues of $1.3M. Lineage Cell Therapeutics's net income of -$4.1M is higher than Lexicon Pharmaceuticals's net income of -$25.3M. Notably, Lineage Cell Therapeutics's price-to-earnings ratio is -- while Lexicon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lineage Cell Therapeutics is 20.64x versus 9.26x for Lexicon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Vaxart has a net margin of -275.57% compared to Lineage Cell Therapeutics's net margin of -74.68%. Lineage Cell Therapeutics's return on equity of -22.68% beat Vaxart's return on equity of -94.14%.

Lineage Cell Therapeutics has a consensus price target of $3.92, signalling upside risk potential of 318.81%. On the other hand Vaxart has an analysts' consensus of $4.67 which suggests that it could grow by 843.72%. Given that Vaxart has higher upside potential than Lineage Cell Therapeutics, analysts believe Vaxart is more attractive than Lineage Cell Therapeutics.

Lineage Cell Therapeutics has a beta of 1.517, which suggesting that the stock is 51.713% more volatile than S&P 500. In comparison Vaxart has a beta of 1.255, suggesting its more volatile than the S&P 500 by 25.549%.

Lineage Cell Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vaxart offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lineage Cell Therapeutics pays -- of its earnings as a dividend. Vaxart pays out -- of its earnings as a dividend.

Lineage Cell Therapeutics quarterly revenues are $1.5M, which are smaller than Vaxart quarterly revenues of $20.9M. Lineage Cell Therapeutics's net income of -$4.1M is higher than Vaxart's net income of -$15.6M. Notably, Lineage Cell Therapeutics's price-to-earnings ratio is -- while Vaxart's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lineage Cell Therapeutics is 20.64x versus 2.26x for Vaxart. Usually stocks with elevated PS ratios are considered overvalued.